D-dimer assay is used to stratify patients with unprovoked venous thromboembolism (VTE)
for the risk of recurrence. However, this approach was never evaluated since direct oral …

Vaccination against communicable diseases is crucial for disease prevention, but this
practice poses challenges to healthcare professionals in patients with haemophilia. Poor …

Comprehensive evidence-based guidelines and well-validated assessment scales for pain
in people with hemophilia (PwH) are needed. Here, we report 28 statements covering five …

Introduction Factor IX replacement therapy is used for treatment and prophylaxis of bleeding
in haemophilia B. rIX‐FP is an extended half‐life albumin‐fusion protein, which, in clinical …

Simple Summary Response to TACE is a surrogate marker of tumor aggressive biology, with
manifold practical implications. In turn, inflammation-based scores are biomarkers of the …

Activated partial thromboplastin time (aPTT) is a fundamental screening test for coagulation
disturbances. An increased aPTT ratio is quite common in clinical practice. How the …

Diagnosis of antiphospholipid syndrome (APS) requires the presence of a clinical criterion (thrombosis
and/or pregnancy morbidity), combined with persistently circulating …

Recombinant porcine factor VIII (rpFVIII) is indicated for treating bleeding episodes in
acquired haemophilia A, but there are few data regarding laboratory methods to adequately …

Life expectancy for persons with hemophilia (PWH) has considerably increased in the last
decades as a direct result of the availability of modern therapies to control the clotting defect. …

Objectives To evaluate pattern of use and clinical outcomes in pediatric/adolescent patients
enrolled in the IDEAL study. Methods This post‐hoc analysis of IDEAL retrospective‐…